Scilex (NASDAQ:SCLX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, Zacks reports.
Scilex Trading Down 4.3 %
NASDAQ SCLX traded down $0.02 during trading on Friday, reaching $0.45. 1,210,231 shares of the company's stock were exchanged, compared to its average volume of 1,365,469. The firm has a market capitalization of $86.11 million, a PE ratio of -0.31 and a beta of 1.06. Scilex has a fifty-two week low of $0.38 and a fifty-two week high of $2.63. The company's fifty day simple moving average is $0.55 and its 200-day simple moving average is $1.00.
Insider Activity
In related news, insider Jaisim Shah purchased 32,000 shares of the stock in a transaction dated Tuesday, October 29th. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $31,680.00. Following the acquisition, the insider now directly owns 109,333 shares in the company, valued at approximately $108,239.67. The trade was a 41.38 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have acquired 70,888 shares of company stock worth $53,835 in the last 90 days. Company insiders own 8.73% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on SCLX shares. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Scilex in a research report on Monday, October 21st. Alliance Global Partners started coverage on Scilex in a report on Wednesday, October 16th. They set a "buy" rating and a $14.00 price objective on the stock.
View Our Latest Stock Analysis on Scilex
Scilex Company Profile
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scilex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.
While Scilex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
